Organic Active Ingredients TRIZ Cases

Continuous distillation concentrates microbial or marine oils into high-DHA ester fractions while reducing process time, cost, and isomerization.

Indoleacetic acid derivatives improve antitussive and antiasthmatic effects while reducing side effects and safety limits of existing drugs.

A 5'-acetoacetyl uridine ester improves oral uptake and releases both uridine and acetoacetate for cerebral energy failure disorders.

Structural changes in domide molecular glue derivatives improve anti-tumor activity while lowering toxicity, including for low receptor expression tumors.

A succinic acid salt crystal form improves solubility, stability, and handling of complement factor B inhibitors for reproducible drug manufacturing.

Amide-linked orotic acid derivatives improve water and alcohol solubility while preserving melanin inhibition and skin whitening activity.

Modular PROTAC degraders bind MLLT1 and MLLT3 and recruit E3 ligase to overcome weak modulation and enable selective cancer targeting.

An amorphous BMS-986165 dispersion in HPMCAS maintains stability and bioavailability under elevated gastric pH while enabling colon release.

Thermal micropores help a triptan patch cross the stratum corneum, improving migraine drug delivery while reducing skin irritation.

Low-dose tacrolimus activates the BMP-SMAD axis via FKBP12 to prevent muscle atrophy and promote hypertrophy without immunosuppression.

Deuterium-tuned Helios degraders improve IKZF2 selectivity and metabolic stability while reducing Treg immunosuppressive activity.

Substituted heterocyclic compounds inhibit Tyk2 signaling while lowering efflux ratios, improving IL-12, IL-23, and IFNα pathway modulation.

Specific Lactobacillus mucosae strains with soluble dietary fiber modulate the gut microbiome to reduce metabolic syndrome markers.

Combining antibiotics with an aryladamantane compound helps counter cancer resistance while improving cytotoxicity, apoptosis, and IL-6 reduction.

Stabilized mRNA in lipid nanoparticles enables sustained therapeutic protein production without genomic integration risks.

Small molecules that modulate PTPN2 boost lymphoid cell activity, offering a lower-cost alternative to complex CAR-T manufacturing.

Protein lysine methyltransferase inhibitors based on quinoxaline-2,3-diamines target juvenile schistosomes, resistant liver flukes, and MRSA.

Immediate IV cangrelor bridges the post-surgery gap before aspirin, helping prevent acute shunt thrombosis in neonates and other pediatric patients.

An amide and alkyl lactate solvent system keeps high-content abamectin concentrates stable in cold storage and prevents crystallization after dilution.

Isookanin suppresses JAK1, TLR-2, COX-2, and kallikrein-5 to treat inflammation while avoiding skin irritation and cytotoxicity.

F(ab')2-based humanized 4-1BB antibodies preserve T cell activation and anti-tumor effects while reducing hepatotoxicity and thrombocytopenia.

A microfabricated cardiac anisotropic sheet enables human cardiomyocyte assays to detect conduction changes and reentrant arrhythmias.

Dry powder epinephrine with controlled particle size improves nasal deposition and absorption while remaining simple for layperson emergency use.

Multiple nitric oxide donor groups on dendrimers or silica improve release control, stability, and tissue-targeted delivery.

Small-molecule CFTR activators increase tear secretion and normalize stool output to treat dry eye and constipation more effectively.

Systemic lotilaner dosing eradicates ticks attached to humans, helping prevent Lyme and other vector-borne disease transmission.

Ni-NTA lipidoid nanoparticles bind His-tagged proteins via nickel coordination, enabling less invasive intracellular delivery and stronger genome editing activity.

A continuous burst-release coat around centanafadine particulates balances fast onset with prolonged and enteric release in high-dose bead formulations.

Ligand-guided constructs use receptor-mediated uptake and membrane penetration to deliver toxic payloads into resistant tumor cells.

Directing pooled human IgG to the olfactory epithelium bypasses the blood-brain barrier, lowering dose and systemic exposure in CNS treatment.

Removing magnesium stearate and using filgotinib maleate Form I with fumaric acid improves formulation stability and bioavailability.

Targeting P2X4 with a benzene-ring scaffold improves antagonistic activity, selectivity, metabolic stability, and toxicity profile for cough therapy.

A dCas9-VP64 and guide RNA approach activates LAMA1 in muscle to compensate for laminin α2 deficiency in MDC1A.

Enzyme-labile protecting groups enable physiological cross-linking of nanostructures, improving bioconjugation stability for delivery and detection.

Oral WX-671 inhibits TMPRSS2 to block coronavirus entry into host cells, lowering viral load while limiting cytotoxicity.

Balanced water and cosolvent levels plus actuator geometry keep ipratropium bromide stable and doses consistent in an MDI.

Androstane derivatives selectively activate SERCA2a with limited Na+/K+ ATPase inhibition, supporting oral heart failure treatment with lower arrhythmogenic risk.

Small-molecule AAT modulators restore protease regulation and reduce hepatic aggregation to address both lung and liver AATD.

Using phospholipid ether carriers, these conjugates improve tumor-selective uptake and cytotoxicity while limiting off-target toxicity in healthy cells.

An oral HPC regimen uses sustained dosing from 14 weeks to maintain therapeutic levels and improve preterm birth prevention versus injections.

A stepwise route combines coupling, bromination, and hydrogenation to scale P2X3 antagonist synthesis for clinically useful quantities.

Small-molecule STING inhibitors curb excessive signaling to treat cancer-linked inflammation and autoinflammatory disorders.

Targeting the IL-4 receptor helps treat resistant atopic dermatitis while reducing biomarkers, pruritus, and dependence on topical corticosteroids.

A 3D triazole-linked polymer conjugate enables sustained ocular drug release, then biodegrades for rapid clearance after treatment.

Sub-anesthetic ketamine alone or with NAP raises ADNP expression while limiting neurotoxicity in ADNP syndrome and related conditions.

Biomarker-guided TGF-β2 suppression paired with irinotecan improves anti-tumor response while helping avoid drug and cross-resistance.

Dual EGFR and B7-H3 binding helps address resistance and multi-pathway limits while boosting ADCC and antibody stability.

Adding at least 5% carbohydrate to an L-tryptophan or L-tyrosine oral liquid promotes insulin response and improves brain uptake.

Site-specific PEGylation at a defined FGF-21 residue creates a homogeneous liquid formulation with longer half-life and 12-month stability.

Cannflavins A, B, and C inhibit Trk signaling to reduce cancer cell viability and invasion while limiting cytotoxicity to healthy cells.